Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
13 mai 2019 16h00 HE
|
Capricor Therapeutics, Inc.
On Track to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, May 13, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics...
Capricor Therapeutics to Present First Quarter 2019 Financial Results and Recent Corporate Update on May 13
06 mai 2019 16h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, May 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...
Capricor Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
28 mars 2019 16h00 HE
|
Capricor Therapeutics, Inc.
Plan to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, March 28, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics...
Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy
06 févr. 2019 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that it has resumed per protocol dosing of patients...
Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Novel Cell Therapy
24 janv. 2019 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Neurology®, an international peer-reviewed journal, on Wednesday published the results of the HOPE-Duchenne clinical trial that evaluated the safety...
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA
22 janv. 2019 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that it had positive outcomes in its comprehensive...
Capricor Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
13 nov. 2018 16h01 HE
|
Capricor Therapeutics, Inc.
To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the...
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial
12 nov. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
Focus will be on Milestones for Development and Commercialization CAP-1002 Therapy for Duchenne Muscular Dystrophy LOS ANGELES, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:...
Capricor Therapeutics to Present Corporate Overview and Poster at Action Duchenne International Conference
08 nov. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
Research Found Exosomes Increased Exercise Capabilities and Muscle Activity in a Mouse Model of Duchenne Muscular Dystrophy LOS ANGELES, Nov. 08, 2018 (GLOBE NEWSWIRE) -- During the Action...
Capricor Therapeutics to Participate in Upcoming Conferences
22 oct. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
Presentations to Focus on Company’s Exosome-based and Duchenne Muscular Dystrophy Therapies LOS ANGELES, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Linda Marbán, Ph.D, CEO of Capricor Therapeutics, Inc....